Ticam1 Antibody

What is TICAM1 and why is it important in immunological research?

TICAM1 (Toll-interleukin 1 receptor domain-containing adaptor molecule 1), also known as TRIF, is an adapter protein that plays a crucial role in innate immunity against invading pathogens. It serves as an adaptor used by TLR3, TLR4 (through TICAM2), and TLR5 to mediate NF-kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis . TICAM1 is particularly important in dsRNA-TLR3-dependent production of IFN-β, forming part of the MyD88-independent cellular immune response . Research has demonstrated its critical role in anti-viral defense mechanisms, making it a significant target for immunological studies .

What are the key structural domains of TICAM1 that antibodies typically target?

TICAM1 contains several functional domains that can be targeted by various antibodies:

• TIR domain: Involved in receptor binding

• N-terminal region: Recruits TBK1 and IKKi, which phosphorylate IRF3

• C-terminal region: Recruits RIP1 and induces apoptosis through FADD/caspase cascade

Available antibodies target different regions including:

• N-terminal region (aa 1-272)

• Middle region (aa 263-526, aa 443-685)

• C-terminal region (aa 663-712, aa 693-708)

What is the difference between polyclonal and monoclonal antibodies for TICAM1 detection?

What are the validated applications for TICAM1 antibodies?

Based on the scientific literature and product information, TICAM1 antibodies have been validated for multiple applications:

How should researchers design experiments to detect TICAM1's interactions with other proteins?

When studying TICAM1's protein interactions with partners like Act1, IL-17RA, or TLR3:

• Co-immunoprecipitation method:

  • Lyse cells in non-denaturing buffer preserving protein-protein interactions

  • Immunoprecipitate with anti-TICAM1 antibody (such as sc-514384 AC)

  • Detect interacting proteins via Western blot with appropriate antibodies

• Proximity Ligation Assay (PLA):

  • PLA signals showing colocalization of FLAG-tagged Act1 with HA-tagged TICAM-1 can be detected in the cytoplasm

  • The number of signals may be reduced after stimulation (e.g., IL-17A)

  • Use anti-TICAM1 antibodies compatible with IF applications

• Important controls:

  • Include stimulated and unstimulated conditions as the physical interactions may change upon stimulation

  • Negative controls with irrelevant antibodies

  • Positive controls with known interaction partners

How can researchers validate TICAM1 antibody specificity using knockout systems?

Establishing proper controls is critical for TICAM1 antibody validation:

• Using CRISPR-Cas9 TICAM1 knockout cells:

  • Generate TICAM1 KO cell lines using CRISPR-Cas9 system (as described in search result )

  • Confirm knockout by genomic sequencing and functional assays

  • Compare antibody reactivity between wild-type and knockout cells by Western blot

  • A specific antibody should show no band in the knockout sample

• Using siRNA knockdown:

  • Transfect cells with TICAM1-specific siRNA

  • Confirm knockdown efficiency by qRT-PCR

  • Compare antibody reactivity in control vs. knockdown samples

  • Expect significant reduction but not complete absence of signal with siRNA

• Reintroduction experiments:

  • Reintroduce TICAM1 expression in knockout cells

  • Verify recovery of antibody staining pattern

  • This confirms specificity and rules out off-target effects

What controls should be included when using TICAM1 antibodies in functional studies?

When studying TICAM1 function in pathways such as TLR3 signaling:

• Positive controls:

  • Include stimulation with known TICAM1 activators (e.g., poly I:C for TLR3 pathway)

  • Verify expected downstream effects (IFN-β induction)

• Negative controls:

  • Include TICAM1 knockout/knockdown controls

  • Monitor key functional readouts (e.g., IFN-β expression, NF-κB activation)

  • Example: TICAM1 knockdown dramatically reduced IFN inductions, which elevated RV production

• Pathway-specific controls:

  • Compare with MyD88-dependent pathway activation

  • Use specific inhibitors of downstream components

  • Include time-course experiments to capture temporal dynamics of activation

How should researchers resolve discrepancies in TICAM1 molecular weight detection?

TICAM1 antibodies detect proteins with apparent molecular weights ranging from 66-110 kDa, which can cause confusion:

• Understanding molecular weight variations:

  • Calculated molecular weight: 76 kDa (for 712 aa protein)

  • Observed molecular weights: 66-76 kDa or ~110-113 kDa

  • These discrepancies may result from:

    • Post-translational modifications

    • Different protein isoforms

    • Cell/tissue-specific processing

• Resolution strategies:

  • Run positive control samples alongside experimental samples

  • Use multiple antibodies targeting different epitopes

  • Include knockout/knockdown controls to confirm specificity

  • Consider phosphatase treatment to eliminate phosphorylation-induced shifts

• Data interpretation guidance:

  • Document the specific molecular weight observed in your experimental system

  • Compare with literature reports using same cell/tissue types

  • Consider running gradient gels for better resolution

What are common false positives/negatives when using TICAM1 antibodies, and how can they be addressed?

How can TICAM1 antibodies be utilized to study its role in IL-17-mediated inflammatory responses?

Research has revealed TICAM1's unexpected role in IL-17 signaling, which can be studied using antibodies:

• Experimental approach to study TICAM1-Act1 interactions:

  • Co-immunoprecipitation: Using anti-TICAM1 antibodies to pull down complexes and detect Act1

  • Proximity ligation assay (PLA): Detecting colocalization of TICAM1 and Act1

  • Functional readouts: Measure IL-17A-induced CXCL1/CXCL2 expression

• Key findings from this approach:

  • TICAM1 physically binds Act1 in resting and IL-17A-stimulated cells

  • TICAM1 inhibits the interaction between IL-17RA and Act1

  • TICAM1 functions as a negative regulator in IL-17A-mediated inflammatory responses

  • TICAM1 knockout enhances inflammatory cytokine production

• Experimental controls:

  • Compare wild-type vs. TICAM1 knockout models

  • Use IL-17A stimulation time course (interactions change over time)

  • Include both in vitro and in vivo models

What methodological approaches are recommended for studying TICAM1's dual role in TLR3 and IL-17 signaling pathways?

TICAM1 has context-dependent roles in different signaling pathways that require careful experimental design:

• Pathway-specific stimulation protocols:

  • TLR3 pathway: Stimulate with poly I:C (synthetic dsRNA)

  • IL-17 pathway: Stimulate with recombinant IL-17A

  • Combined stimulation: Test for pathway cross-regulation

• Readout measurements:

  • TLR3 pathway: IFN-β production, IRF3 phosphorylation

  • IL-17 pathway: CXCL1/CXCL2 expression, NF-κB activation

  • Use both mRNA (qRT-PCR) and protein (ELISA, Western blot) analyses

• Time-course considerations:

  • TLR3 response: Often peaks 6-12 hours post-stimulation

  • IL-17 response: Can be measured 6-24 hours post-stimulation

  • Physical interactions change over time after stimulation

• In vivo validation models:

  • DTH (delayed type hypersensitivity) model using DNFB

  • EAE (experimental autoimmune encephalomyelitis) model

  • IL-17A intraperitoneal or intranasal injection models

How should researchers interpret contradictory findings about TICAM1 function in different model systems?

Contradictions in TICAM1 research findings need careful analysis:

• Context-dependent functions:

  • TICAM1 is essential for TLR3-mediated IFN production (positive regulator)

  • TICAM1 suppresses IL-17-mediated inflammatory responses (negative regulator)

  • These opposing functions are pathway-specific and not contradictory

• Cell type-specific effects:

  • Effects observed in HeLa cells vs. immune cells may differ

  • Compare results across multiple cell types (HeLa, MEFs, macrophages, etc.)

  • Verify in primary cells vs. cell lines

• Resolution approach:

  • Determine pathway-specific protein complexes using immunoprecipitation

  • Investigate temporal dynamics of signaling complex formation

  • Consider subcellular localization differences

  • Use domain-specific mutants to identify critical regions for each function

• Translational considerations:

  • Connect in vitro findings to disease models (e.g., EAE, viral infections)

  • Consider species differences when comparing human vs. mouse models

  • Validate with multiple experimental approaches

What are the optimal conditions for immunoprecipitation of TICAM1 and its binding partners?

For successful co-immunoprecipitation of TICAM1 complexes:

• Lysis buffer composition:

  • Use non-denaturing buffers containing:

    • 20 mM Tris-HCl (pH 7.5)

    • 150 mM NaCl

    • 1% Nonidet P-40 or Triton X-100

    • Protease and phosphatase inhibitors

• Antibody selection:

  • Choose antibodies validated for IP applications:

    • ab302562 - Rabbit recombinant monoclonal

    • sc-514384 AC - Mouse monoclonal with agarose conjugate

  • For co-IP, target different proteins with antibodies from different species

• Technical considerations:

  • Pre-clear lysates to reduce non-specific binding

  • Include appropriate negative controls (isotype control antibodies)

  • Consider crosslinking for transient interactions

  • Test both resting and stimulated conditions (interactions change upon stimulation)

• Detection methods:

  • Use clean detection antibodies from different species

  • Consider using TrueBlot secondary antibodies to avoid detection of IP antibody

What tissue fixation and antigen retrieval methods are optimal for TICAM1 detection in immunohistochemistry?

Based on validated protocols for TICAM1 IHC:

• Tissue fixation:

  • Formalin fixation is standard for most tissues

  • Paraformaldehyde (4%) for frozen sections

  • Fixation time should be optimized (typically 24-48 hours for FFPE)

• Antigen retrieval methods:

  • Heat-induced epitope retrieval is recommended:

    • TE buffer pH 9.0 (primary recommendation)

    • Citrate buffer pH 6.0 (alternative method)

  • Microwave or pressure cooker heating for 10-20 minutes

• Protocol optimization:

  • Antibody dilutions typically range from 1:50-1:500

  • Include known positive tissues (human brain, testis, or liver tissue)

  • Signal amplification may be required for low-expression tissues

  • Block endogenous peroxidase activity before antibody incubation

How can TICAM1 antibodies be utilized in autoimmune disease research?

Research has demonstrated TICAM1's role in autoimmunity, which can be investigated using antibodies:

• Experimental autoimmune encephalomyelitis (EAE) model:

  • TICAM1 knockout exacerbates EAE pathogenesis

  • Increased accumulation of CD4+ and F4/80+ cells in spinal cord

  • EAE severity is IL-17A-dependent (blocked by anti-IL-17A antibody)

• Research approaches:

  • Compare TICAM1 expression levels in disease vs. healthy tissue

  • Analyze TICAM1-interacting proteins in disease states

  • Monitor TICAM1 expression during disease progression

  • Correlate TICAM1 expression with disease severity

• Immunostaining applications:

  • Tissue distribution analysis in affected organs

  • Co-localization with inflammatory cell markers

  • Changes in subcellular localization during disease

• Therapeutic implications:

  • TICAM1 function as a negative regulator of IL-17 signaling suggests potential therapeutic targeting

  • Modulating TICAM1-Act1 interaction could influence autoimmune disease progression

What methodological considerations are important when studying TICAM1's role in viral defense mechanisms?

TICAM1 plays a critical role in antiviral responses that can be studied with appropriate methods:

• Experimental viral models:

  • TICAM1 knockdown dramatically reduced IFN inductions

  • This elevated RV (rotavirus) production as measured by:

    • Increase of RV genomic RNA

    • Increase of mature RV coat proteins VP0 and VP2

• Critical controls:

  • Compare TICAM1 knockout vs. wild-type responses

  • Include TLR3 knockdown/knockout controls

  • Monitor downstream effectors (IFN-β and IFN-λ)

• Detection methods:

  • Western blot for TICAM1 expression levels

  • qRT-PCR for IFN and inflammatory cytokine induction

  • Viral load quantification (qPCR, plaque assays)

  • Immunofluorescence for subcellular localization during infection

• Human vs. mouse differences:

  • Consider species-specific antibodies when translating between models

  • Human TICAM1 maps to chromosome 19p13.3

  • Pathway conservation should be verified across species